+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 11 Actively Recruiting clinical trials

B

Actively Recruiting

Healthy Volunteer

Researchers are collecting blood and tissue samples from people with and without cancer to help develop and evaluate tests for early cancer detection. This observational study aims to create a blinded reference set of blood samples from cancer and non-cancer patients to validate new blood-based multi-cancer early detection tests. The study also evaluates test performance at the time of initial cancer diagnosis by tumor type and clinical stage. Participants complete a questionnaire at the start of the study and provide blood samples at registration and again 12 months later. Patients diagnosed with cancer may also provide tissue samples at these same times. The study collects these biospecimens to help researchers study and validate early cancer detection assays in the laboratory. During the study, participants are monitored with follow-up at one year after enrollment. Researchers assess the quality and usefulness of the collected blood samples as a blinded reference set for cancer detection tests. The main outcome is the provision of these samples over up to one year, with additional evaluation of test performance by tumor type and stage. Participants involvement includes questionnaires, blood draws, and possible tissue sample collection, with no treatment interventions involved.

Age: 40Years - 75YearsAll Genders
751 locations
S

Actively Recruiting

Healthy Volunteer

This research aims to compare the safety and effectiveness of two types of multifocal contact lenses, ACUVUE4 OASYS MAX 1-Day Multifocal and DAILIES4 AquaComfort Plus4 Multifocal. The study is designed as a randomized, single-masked clinical trial with two parallel groups to evaluate visual acuity and ocular safety in adults aged 40 to 70 years. Participants will be monitored for both near and distance vision performance as well as any lens-related eye events. Participants will be randomly assigned to wear either the Senofilcon A lens ACUVUE4 OASYS MAX 1-Day Multifocal or the Nelfilcon A lens DAILIES4 AquaComfort Plus4 Multifocal for the duration of the study. The study consists of four visits where the lenses performance is assessed at one week and one month after initial fitting. Both lenses are soft multifocal contact lenses designed to correct presbyopia and improve visual acuity at various distances. During the study, participants will undergo evaluations of binocular visual acuity at distance, intermediate, and near ranges, along with monitoring for ocular adverse events and slit lamp findings. The primary outcomes measured include visual acuity at one week and the incidence of lens-related eye issues up to one month. This study requires participants to attend four visits over the course of the study period, which lasts approximately one month after lens fitting.

Age: 40Years - 70YearsAll GendersPhase Not Applicable
11 locations
P

Actively Recruiting

Researchers are evaluating a treatment approach for early-stage hormone-sensitive, HER-2 negative breast cancer with an Oncotype recurrence score of 18 or less. This Phase III trial compares breast conservation surgery with endocrine therapy alone against breast conservation surgery with both radiation and endocrine therapy. The goal is to see if skipping radiation after lumpectomy is not worse in preventing cancer recurrence in the same breast. Participants will be randomly assigned to one of two groups. One group will receive radiation therapy to the breast plus at least five years of endocrine therapy with drugs such as Tamoxifen, Anastrozole, Letrozole, or Exemestane. The other group will receive endocrine therapy only for at least five years without radiation. Radiation must start within 12 weeks of surgery if assigned. Endocrine therapy dosing and schedule are determined by the treating doctor. During the study, participants will have regular follow-ups up to five years to monitor cancer recurrence in the breast and elsewhere, survival, and breast preservation. Assessments will include clinical exams, imaging like mammograms or MRI, and pathology reviews. The main outcome is time to invasive or noninvasive breast tumor recurrence within five years. Some measures will continue through an average of 15 years, including breast conservation rates. Safety and overall health will be monitored throughout and after treatment.

Age: 50Years - 70YearsAll GendersPhase 3
832 locations
P

Actively Recruiting

Researchers are evaluating whether adding adjuvant chemotherapy to ovarian function suppression plus endocrine therapy improves invasive breast cancer-free survival in premenopausal women with early-stage estrogen receptor-positive, HER2-negative breast cancer and specific recurrence scores. This Phase III trial addresses a critical need for better treatment options in younger women, who face higher risks of breast cancer recurrence and mortality. Participants will receive one of two treatment approaches ovarian function suppression combined with an aromatase inhibitor for five years, or chemotherapy followed by the same hormonal treatment. The choice of chemotherapy, aromatase inhibitor, and ovarian suppression method is determined by the investigator, with options such as goserelin, leuprolide, or triptorelin administered monthly or every three months. Endocrine therapy beyond five years is at the investigators discretion, and bilateral oophorectomy may replace ovarian suppression if desired. During the trial, participants will be monitored for invasive breast cancer-free survival over 11 years following randomization. Additional outcomes include overall survival, disease-free survival, distant recurrence, and treatment-related symptoms such as menopausal effects and pain during aromatase inhibitor therapy. The study involves regular assessments to evaluate these outcomes and ensure participant safety throughout the extended follow-up period.

Age: 18Years - 60YearsFEMALEPhase 3
1276 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
S

Actively Recruiting

Researchers are investigating the safety and effectiveness of Phentolamine Ophthalmic Solution POS in adults who have previously undergone keratorefractive surgery and now experience decreased vision under low light, or mesopic, conditions. This Phase 3 trial compares POS to a placebo to determine if POS can improve night vision in this group. Participants will be randomly assigned to receive either 0.75% Phentolamine Ophthalmic Solution or a placebo eye drop once daily for two weeks. Weekly clinic visits during this period will include checkups and tests. Participants will also maintain a diary to record their daily medication use each evening. Throughout the study, participants will undergo various vision tests and questionnaires to measure changes in visual acuity under mesopic conditions and effects on night driving difficulties. Safety and vision improvements will be closely monitored during the two-week treatment and at follow-up visits. The trial is expected to last until August 2027.

Age: 18Years +All GendersPhase 3
20 locations
E

Actively Recruiting

This research aims to evaluate a technology-based collaborative care model called RI-SPHERES among postpartum patients with hypertensive disorders of pregnancy HDP. The trial will test whether RI-SPHERES is not worse than a standard self-measured blood pressure SMBP program in controlling persistent hypertension six weeks after delivery and improving preventive care attendance within one year. The study addresses challenges like low adherence to blood pressure checks due to barriers such as childcare and transportation, especially in racial or ethnic minority groups. Participants will be randomly assigned to one of two groups the RI-SPHERES group or the standard SMBP program group. The RI-SPHERES group will use a LTE-enabled blood pressure cuff syncing to a smartphone app that sends automated reminders and adaptive messages based on blood pressure readings and symptoms, with a nurse practitioner-led collaborative care team supporting patients. The first six weeks focus on blood pressure control, then shift to preventive care support for up to one year. The standard SMBP group will manually enter blood pressure readings into an electronic record to be reviewed by clinical staff, with recommendations for monthly blood pressure checks and preventive care after six weeks postpartum. Participants will be involved for one year postpartum, during which blood pressure measurements, preventive care visits, and maternal health outcomes will be monitored. Assessments include short- and long-term blood pressure control, severe maternal morbidity, emergency visits, hospital readmissions, medication adjustments, and patient satisfaction. The study will also evaluate equity in care related to race, ethnicity, language, and geography. Data will be collected through the app, electronic medical records, and regular communications with the study team to track adherence and health outcomes.

Age: 18Years - 60YearsFEMALEPhase Not Applicable
5 locations
C

Actively Recruiting

Researchers are studying perinatal health outcomes in Rhode Island, focusing on improving maternal and infant health by addressing social determinants of health SDOH such as food, housing, and transportation. The project aims to reduce adverse outcomes and racial disparities by integrating hospital services with community health workers, doulas, and community organizations. This effort is structured as a stepped wedge cluster randomized trial across six prenatal clinics over four years. The study involves implementing the Community-based Maternal Support Services COMSS program, which includes universal screening for risk factors at multiple prenatal and postpartum visits. Patients who screen positive receive coordinated care from care managers and community health workers, including doula care and referrals to address social needs. The intervention is introduced sequentially to all clinics, and data will be collected before and after the program to evaluate its impact. Participants will undergo screenings at their first prenatal visit, second and third trimesters, delivery, and 2-6 weeks postpartum. Those identified with risks will receive ongoing support and follow-up, with care continuing until at least three months postpartum before transitioning to primary care. Researchers will assess outcomes such as rates of severe maternal morbidity and mortality, cesarean births, prenatal care adequacy, postpartum depression screening, substance abstinence during pregnancy, infant death, and preterm birth.

All AgesFEMALEPhase Not Applicable
7 locations
M

Actively Recruiting

Researchers are conducting a multicenter screening study to determine how common the KIT D816V mutation is among people suspected of having clonal mast cell disease. This study focuses on various groups, including those with symptoms of mast cell activation, certain related diseases, specific blood cancers, and skin mast cell involvement. Participants are divided into four cohorts based on their symptoms or diagnoses. The study involves collecting blood or bone marrow samples after informed consent and medical history review. The main goal is to detect the KIT D816V mutation in peripheral blood using advanced molecular techniques on the first day of participation. During the study, participants provide samples and relevant health information. Researchers measure the presence of the mutation using digital droplet PCR and a super rolling circle amplification assay. The study continues until July 2028, with follow-up evaluations focusing on mutation prevalence to better understand this condition.

Age: 18Years +All Genders
26 locations
P

Actively Recruiting

Researchers are evaluating a phase III trial comparing shorter chemotherapy-immunotherapy without anthracycline drugs to the usual chemo-immunotherapy for treating early-stage triple negative breast cancer TNBC. This study aims to see if the shorter treatment works as well as the usual anthracycline-containing treatment. The trial also assesses patient-reported outcomes like fatigue and physical function, as well as safety and survival measures. It involves participants with specific stages of TNBC and includes detailed evaluations of tumor response and immune markers. Participants are randomly assigned to one of two treatment groups. One group receives paclitaxel, carboplatin, and pembrolizumab followed by doxorubicin, cyclophosphamide, and pembrolizumab, then surgery, with possible pembrolizumab after surgery. The other group receives docetaxel, carboplatin, and pembrolizumab prior to surgery, with possible pembrolizumab after surgery. Blood samples may be collected throughout the trial for research purposes. During the study, participants undergo surgery after chemotherapy-immunotherapy. They are followed every six months for two years, then annually up to five years. Assessments include breast cancer event-free survival, pathological response, distant relapse-free survival, overall survival, adverse events, and patient-reported fatigue and physical function. Quality of life and other patient-reported symptoms are also evaluated. Specimens are banked for future research. The total participation may last up to five years from registration.

Age: 18Years +All GendersPhase 3
963 locations

1-10 of 11

1